Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 4, 2005, Pages 189-195

  Lopez Pousa S ^a   Turon Estrada, A ^a   Garre Olmo, J ^a   Pericot Nierga, I ^a   Lozano Gallego, M ^a   Vilalta Franch, M ^a   Hernandez Ferrandiz M ^a   Morante Munoz V ^a   Isern Vila, A ^a   Gelada Batlle, E ^a   Majo Llopart J ^a  

^a HOSPITAL SANTA CATERINA   (Spain)

Author keywords

Alzheimer's disease; Anticholinesterase inhibitors; Donepezil; Galantamine; Mini mental state examination; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH CENTER; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEMORY; MINI MENTAL STATE EXAMINATION; MODEL; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SAMPLE; SCORING SYSTEM; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PIPERIDINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 20244362525     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083498     Document Type: Article

References (25)

1. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
2. White KG, Ruske AC: Memory deficits in Alzheimer's disease: The encoding hypothesis and cholinergic function. Psychon Bull Rev 2002;9:426-437.
3. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-1245.
4. Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer's disease; in: Cochrane Library, Issue 1, 2003. Update Software.
5. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer's disease; in: Cochrane Libraiy, Issue 1, 2003. Update Software.
6. Olin J, Schneider L: Galantamine for Alzheimer's disease; in: Cochrane Library, Issue 1, 2003. Update Software.
7. León O, Montero J: Diseño de investigaciones. Madrid, McGraw Hill, 1995.
8. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. Roth M, Huppert FA, Tym E, Mountioy CQ: CAMDEX: The Cambridge Examination for Mental Disorders for the Elderly. Cambridge, Cambridge University Press, 1988.
11. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E, Garre-Olmo J, Lozano-Gallego M, Hernandez-Ferrandiz M, et al: Tolerancia y acontecimientos adversos del tratamiento con inhibidores de la acetilcolinesterasa en una muestra clínica de pacientes con enfermedad de Alzheimer de severidad mínima y ligera durante un periodo de 6 meses. Rev Neurol 2003;36:421-424.
13. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
14. Corey-Bloom J, Anand R, Veach J, for the ENA713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
15. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445-1449.
16. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al: A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-446.
17. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, et al: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-789.
18. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al: A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:58-67.
19. Han L, Cole M, Bellavance F, McKusker J, Primeau F: Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: A meta-analysis. Int Psychogeriatr 2000;12:231-247.
20. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al: A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
21. Knopman DS, Knapp MJ, Gracon SI, Davis CS: The Clinician Interview-Based Impression (CIBI): A clinician's global rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
22. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-422.
23. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al: Donepezil Nordic Study Group: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
24. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W: APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:69-77.
25. Adler G, Brassen S, Chwalek K, Dieter B, Teufel M: Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 2004;75:292-294.